Solid Lipid Nanoparticles of Guggul Lipid as Drug Carrier for Transdermal Drug Delivery

Table 3

Physical characterization of SLN after stability studies at 40°C ± 2°C and 75% ± 5% RH.

Physical characterization Parameters	Days	Formulation Code
		GMN-3	SAN-3	GLN-3
Size (nm)	0th	124.2±4.1	137.6±6.23	117±1.7
	30th	126.3±4.6	189.4±5.19	117.8±1.4
	90th	136.8±3.2	198.2±5.64	119±2.6
	180th	154.2±5.4	212.1±4.14	126±3.2
PDI	0th	0.31±0.028	0.40±0.048	0.22±0.028
	30th	0.32±0.021	0.41±0.032	0.22±0.071
	90th	0.38±0.035	0.42±0.059	0.23±0.087
	180th	0.39±0.024	0.49±0.035	0.26±0.045
ζ potential (mV)	0th	−23±3.54	−36±4.15	−15±1.43
	30th	−22±3.76	−34±4.52	−16±1.21
	90th	−23±3.18	−30±4.98	−16±1.76
	180th	−20±4.25	−28±3.17	−18±1.65
Entrapment efficiency; (%)	0th	69.96±3.61	59.32±3.59	89.54±1.43
	30th	68.21±4.41	58.87±3.59	89.19±3.32
	90th	67.45±3.13	54.64±3.59	88.34±2.43
	180th	61.18±3.23	46.39±3.59	86.42±1.46
In-vitro % cumulative drug release (in 24 h)	0th	82.07±1.78	88.89±2.34	73.54±1.76
	30th	83.21±1.57	90.48±2.25	74.23±2.23
	90th	85.43±2.32	94.23±2.92	75.12±1.87
	180th	92.45±3.97	96.43±3.54	76.32±2.13

All data expressed as mean ± S.D.; 𝑛=3; 𝑃≤0.05.